Dr. Ferrer Biopharma to Showcase Groundbreaking Research in Post-COVID Treatment at ERS Congress 2023
Leading pharmaceutical research and development company Dr. Ferrer Biopharma proudly announces its participation in the highly anticipated European Respiratory Society (ERS) Congress 2023 , scheduled in Milan, Italy, from September 9th to 13th. During the event, the company will present late-breaking findings from two randomized controlled trials that shed light on the potential of intranasal Chlorpheniramine to treat post-COVID-19 long-term symptoms.
The ERS Congress serves as a premier platform in respiratory health, featuring the latest advancements in clinical care, scientific research, education, and technology, where experts and researchers worldwide share insights and discoveries, driving progress in respiratory medicine.
Highlighting a pioneering study, the late-breaking abstract by Dr. Ferrer Biopharma introduces Intranasal Chlorpheniramine Maleate (iCPM) as an innovative therapeutic strategy with promising anti-inflammatory and antiviral properties against COVID-19 and respiratory viruses, specifically addressing long-term symptoms. Investigating the effects of this novel approach, Dr. Ferrer Biopharma's presentation delves into the impact of intranasal Chlorpheniramine on post-COVID-19 symptoms, revealing significant improvements in clinical recovery time and alleviation of symptoms like anosmia, ageusia, and cough, as demonstrated by the two randomized trials ACCROS I, and ACCROS III. The subsequent post-trial follow-up highlights Chlorpheniramine's remarkable reduction of post-COVID symptoms by over 90% compared to a placebo.
"The antiviral and anti-inflammatory effect of iCPM can explain the significant impact in reducing time to clinical recovery in the acute illness," said Dr. Franck Rahaghi , Clinical Professor of Medicine and chairman of Cleveland Clinic Florida pulmonary and critical care department, who leads the study. "iCPM may have better impact in reducing long-COVID symptoms. This reformulated treatment could become a cornerstone intervention in addressing the dreaded issue of long-COVID."
"We are excited to unveil the results of our comprehensive research that explores the impact of intranasal chlorpheniramine on post-COVID-19 long-term symptoms," said Dr. Fernando Valerio, Principal Investigator.
The company's participation underscores its dedication to propelling innovation and achieving excellence in respiratory medicine.
About Dr. Ferrer Biopharma:
Dr. Ferrer Biopharma is a pioneering pharmaceutical research and development company dedicated to advancing intranasal medications for treating cough, colds, flu, and allergies. We use advanced technology to bring to the market high-quality, evidence-based, consumer-focused therapies that originated at the bedside.
For more information, please visit DrFerrerBioPharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906892619/en/
Contact information
Daniel Fernández
Marketing Director
+1-954-225-7694
marketing@pulmonary-institute.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IAMPHENOM Europe Expands All-Star Speaker Lineup27.10.2025 15:30:00 EET | Press release
Phenom, an applied AI company that helps organisations hire faster, develop better and retain longer, announced a second wave of confirmed speakers joining its inaugural IAMPHENOM Europe conference — the only applied AI event for human resources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027606156/en/ Phenom announced a second wave of confirmed speakers joining its inaugural IAMPHENOM Europe conference — the only applied AI event for human resources. Featuring visionary keynotes, customer-led breakout sessions, live demonstrations of use-case specific AI agents, and networking opportunities across HR and IT, the in-person event will take place 6 November in Munich. Session topics will include how to: assess AI and automation maturity levels; deploy 25+ AI agents; uphold compliance while navigating European regulations; develop and retain internal talent while attracting external skills; drive unprecedented recruiter
ThetaRay and Kaufman Rossin Announce AI AML Model Validation at Money20/20 USA27.10.2025 15:00:00 EET | Press release
ThetaRay, a global leader in Cognitive AI financial crime compliance, today announced that Kaufman Rossinhas completed an independent validation of its AML Transaction Monitoring and OFAC Screening Modules. Finalized in August 2025, the review confirms that ThetaRay’s AI models demonstrate the governance, transparency, and robustness regulators increasingly expect from AI-driven compliance systems. The announcement will be featured at Money20/20 USA, where the future of finance and compliance technology takes center stage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027724792/en/ A timely milestone in a shifting regulatory landscape In the United States, regulators are sharpening their focus on model risk management. FinCEN’s proposed modernization of the Bank Secrecy Act emphasizes dynamic, risk-based compliance programs and heightened oversight of third-party models. In the European Union, the newly enacted AI Act se
Klarna Launches Memberships: Premium Perks Without Expensive Credit27.10.2025 15:00:00 EET | Press release
Klarna, the global digital bank and payments provider, today unveiled its new global membership program, introducing Premium and Max. The program delivers premium benefits like cashback, travel perks, and lifestyle rewards in a transparent, monthly plan, without the need to take on expensive credit. The launch marks a major step in Klarna’s evolution into a full-scale digital bank helping consumers manage their money with greater value and control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027643962/en/ “We believe consumers shouldn’t have to take on expensive credit to access premium benefits,” said David Sandström, Chief Marketing Officer at Klarna. “For decades, exclusive perks such as airport lounge access, concierge-style subscriptions, and premium travel insurance were only available to elite credit card holders. Klarna is changing that. Through Klarna memberships, consumers can enjoy travel, lifestyle, and dig
inDrive Calls for Justice in Tech Leadership; Launches Global Campaign to Recruit Directors for Child Protection, Education, and Good Governance27.10.2025 15:00:00 EET | Press release
inDrive, the world’s second most downloaded ride-hailing app, has set a bold goal: to positively impact 1 billion people by 2030. To achieve it, the company is strengthening its impact arm and launching “Positions of Purpose,” a global campaign to recruit senior leaders in child protection, education, and governance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027308855/en/ inDrive, a global mobility and urban services platform, extends mission-driven approach from business model to hiring practices. inDrive first challenged the ride-hailing model by allowing riders and drivers to negotiate fares directly, building a business on fairness instead of opaque pricing. Now, the company is challenging what impact hiring should look like — putting social justice roles at the same level of priority and visibility as growth, product, and operations. The campaign introduces three unprecedented roles: Global Director, Family-Base
SLB and Ormat Partner to Accelerate Integrated Geothermal Asset Development and Enhanced Geothermal Systems27.10.2025 15:00:00 EET | Press release
Global energy technology company SLB (NYSE: SLB) and leading geothermal and renewable energy company Ormat Technologies (NYSE: ORA) today announced an agreement to fast-track the development and commercialization of integrated geothermal assets, including enhanced geothermal systems (EGS). EGS is the next generation of geothermal technology, meant to unlock geothermal energy in regions beyond where conventional geothermal resources exist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251025805256/en/ The Ormat geothermal facility Casa Diablo IV, California Together, SLB and Ormat intend to streamline project deployment, from concept to power generation. As part of this effort, they will develop, pilot and scale EGS solutions to enable wide-scale EGS adoption. This collaboration will include the design and construction of an EGS pilot at an Ormat site. Key Highlights: Joint Technology and Project Development: SLB and Ormat w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom